Which has preferable valuation and earnings, EXEL or NTRA?

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.30 $782.57M $3.18 18.56 Natera $2.31B 24.43 -$208.16M -$1.36 N/A

Is EXEL or NTRA more profitable?

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Natera -7.11% -11.38% -7.87%

Does the media refer more to EXEL or NTRA?

In the previous week, Natera had 12 more articles in the media than Exelixis. MarketBeat recorded 21 mentions for Natera and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat Natera's score of 0.13 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Natera 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to EXEL or RVMD?

In the previous week, Exelixis and Exelixis both had 9 articles in the media. Exelixis' average media sentiment score of 0.63 beat Revolution Medicines' score of 0.14 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BIIB or EXEL?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.26 $1.29B $5.65 38.66 Exelixis $2.32B 6.30 $782.57M $3.18 18.56

Is BIIB or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Exelixis 35.33% 42.17% 31.76%

Does the media prefer BIIB or EXEL?

In the previous week, Biogen had 10 more articles in the media than Exelixis. MarketBeat recorded 19 mentions for Biogen and 9 mentions for Exelixis. Biogen's average media sentiment score of 0.74 beat Exelixis' score of 0.63 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNY or EXEL?

In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than Exelixis. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat Alnylam Pharmaceuticals' score of 0.51 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, EXEL or ROIV?

Exelixis has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.30 $782.57M $3.18 18.56 Roivant Sciences $8.26M 2,991.59 -$299.77M -$0.53 N/A

Is EXEL or ROIV more profitable?

Exelixis has a net margin of 35.33% compared to Roivant Sciences' net margin of -3,534.96%. Exelixis' return on equity of 42.17% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Roivant Sciences -3,534.96% -22.94% -21.53%

Does the media favor EXEL or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than Exelixis. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Exelixis. Roivant Sciences' average media sentiment score of 0.64 beat Exelixis' score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exelixis (EXEL) Competitors

$59.02 +0.58 (+0.99%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$59.05 +0.03 (+0.05%)

As of 10/8/2026 07:30 PM Eastern

Compare

EXEL vs. NTRA, RVMD, BIIB, ALNY, and ROIV

Should you buy Exelixis stock or one of its competitors? Exelixis's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Natera?

Exelixis (NASDAQ:EXEL) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Natera had 12 more articles in the media than Exelixis. MarketBeat recorded 21 mentions for Natera and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat Natera's score of 0.13 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Natera	-7.11%	-11.38%	-7.87%

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
Natera	$2.31B	24.43	-$208.16M	-$1.36	N/A

Exelixis has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Natera has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Exelixis currently has a consensus target price of $50.36, indicating a potential downside of 14.68%. Natera has a consensus target price of $353.45, indicating a potential downside of 9.55%. Given Natera's stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 5.1% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Natera beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Revolution Medicines?

Exelixis (NASDAQ:EXEL) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Exelixis has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Exelixis and Exelixis both had 9 articles in the media. Exelixis' average media sentiment score of 0.63 beat Revolution Medicines' score of 0.14 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis presently has a consensus price target of $50.36, indicating a potential downside of 14.68%. Revolution Medicines has a consensus price target of $234.76, indicating a potential upside of 24.79%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

Exelixis has a net margin of 35.33% compared to Revolution Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Revolution Medicines	N/A	-88.20%	-57.85%

Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
Revolution Medicines	$11.58M	3,482.01	-$1.13B	-$8.82	N/A

Summary

Exelixis beats Revolution Medicines on 8 of the 15 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Biogen has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Biogen presently has a consensus target price of $230.00, suggesting a potential upside of 5.30%. Exelixis has a consensus target price of $50.36, suggesting a potential downside of 14.68%. Given Biogen's stronger consensus rating and higher probable upside, equities analysts plainly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

87.9% of Biogen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Biogen had 10 more articles in the media than Exelixis. MarketBeat recorded 19 mentions for Biogen and 9 mentions for Exelixis. Biogen's average media sentiment score of 0.74 beat Exelixis' score of 0.63 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	7 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.26	$1.29B	$5.65	38.66
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Exelixis	35.33%	42.17%	31.76%

Summary

Biogen beats Exelixis on 10 of the 16 factors compared between the two stocks.

How does Exelixis compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.09	$313.75M	$5.38	41.73
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56

In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than Exelixis. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat Alnylam Pharmaceuticals' score of 0.51 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.33% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Exelixis	35.33%	42.17%	31.76%

Alnylam Pharmaceuticals presently has a consensus target price of $366.65, indicating a potential upside of 63.30%. Exelixis has a consensus target price of $50.36, indicating a potential downside of 14.68%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Alnylam Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Exelixis on 11 of the 17 factors compared between the two stocks.

How does Exelixis compare to Roivant Sciences?

Exelixis (NASDAQ:EXEL) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Roivant Sciences had 3 more articles in the media than Exelixis. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for Exelixis. Roivant Sciences' average media sentiment score of 0.64 beat Exelixis' score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A

Exelixis has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Roivant Sciences' net margin of -3,534.96%. Exelixis' return on equity of 42.17% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Exelixis presently has a consensus price target of $50.36, indicating a potential downside of 14.68%. Roivant Sciences has a consensus price target of $45.64, indicating a potential upside of 33.40%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

85.3% of Exelixis shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Exelixis and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.48B	$3.87B	$7.19B	$13.40B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	18.56	13.89	274.65	25.98
Price / Sales	6.30	1,212.93	587.73	88.53
Price / Cash	19.31	117.60	76.82	53.72
Price / Book	7.32	16.11	10.81	6.27
Net Income	$782.57M	-$22.69M	$3.50B	$382.01M
7 Day Performance	1.08%	-2.88%	-1.83%	-1.60%
1 Month Performance	1.18%	-11.16%	-6.34%	-4.63%
1 Year Performance	53.02%	8.32%	3.08%	-0.95%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	3.1209 of 5 stars	$59.02 +1.0%	$50.36 -14.7%	+52.7%	$14.48B	$2.32B	18.56	1,077	Analyst Forecast
NTRA Natera	2.182 of 5 stars	$400.65 -5.9%	$347.02 -13.4%	+127.1%	$57.75B	$2.31B	N/A	6,140	Analyst Forecast Gap Down
RVMD Revolution Medicines	3.7002 of 5 stars	$199.87 -3.8%	$234.33 +17.2%	+293.4%	$42.84B	N/A	N/A	883	Analyst Forecast
BIIB Biogen	3.3675 of 5 stars	$222.89 -0.3%	$230.14 +3.3%	+44.7%	$32.93B	$9.89B	39.45	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.5936 of 5 stars	$223.94 +1.8%	$366.90 +63.8%	-50.2%	$29.97B	$3.71B	41.62	2,770	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors

EXEL vs. NTRA, RVMD, BIIB, ALNY, and ROIV

How does Exelixis compare to Natera?

Summary

How does Exelixis compare to Revolution Medicines?

Summary

How does Exelixis compare to Biogen?

Summary

How does Exelixis compare to Alnylam Pharmaceuticals?

Summary

How does Exelixis compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exelixis (EXEL) Competitors

EXEL vs. NTRA, RVMD, BIIB, ALNY, and ROIV

How does Exelixis compare to Natera?

Does the media refer more to EXEL or NTRA?

Is EXEL or NTRA more profitable?

Which has preferable valuation and earnings, EXEL or NTRA?

Which has more volatility and risk, EXEL or NTRA?

Do analysts recommend EXEL or NTRA?

Do institutionals & insiders believe in EXEL or NTRA?

Summary

How does Exelixis compare to Revolution Medicines?

Which has more risk & volatility, EXEL or RVMD?

Do insiders & institutionals believe in EXEL or RVMD?

Does the media refer more to EXEL or RVMD?

Do analysts recommend EXEL or RVMD?

Is EXEL or RVMD more profitable?

Which has better earnings & valuation, EXEL or RVMD?

Summary

How does Exelixis compare to Biogen?

Which has more volatility & risk, BIIB or EXEL?

Do analysts rate BIIB or EXEL?

Do insiders & institutionals hold more shares of BIIB or EXEL?

Does the media prefer BIIB or EXEL?

Which has stronger earnings & valuation, BIIB or EXEL?

Is BIIB or EXEL more profitable?

Summary

How does Exelixis compare to Alnylam Pharmaceuticals?

Do insiders and institutionals believe in ALNY or EXEL?

Which has higher valuation & earnings, ALNY or EXEL?

Does the media prefer ALNY or EXEL?

Is ALNY or EXEL more profitable?

Do analysts recommend ALNY or EXEL?

Which has more risk and volatility, ALNY or EXEL?

Summary

How does Exelixis compare to Roivant Sciences?

Does the media favor EXEL or ROIV?

Which has preferable valuation and earnings, EXEL or ROIV?

Which has more risk & volatility, EXEL or ROIV?

Is EXEL or ROIV more profitable?

Do analysts rate EXEL or ROIV?

Do insiders and institutionals believe in EXEL or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools